PHARMACY

Study finds link between genes and suicide in Celexa users

BY Allison Cerra

WASHINGTON Research from the National Institute of Mental Health has associated two genetic markers with suicidal thoughts in patients who take the antidepressant drug Celexa, according to an article written by Wired magazine.

The study, which appears in the October issue of the American Journal of Psychiatry, examined genetic material from 1,915 adult patients with major depression who were being treated with citalopram, Celexa’s generic name. Variants of two genes, GRIK2 and GRIA3, increased the likelihood that patients would experience suicidal thoughts.

Both genes, the study indicated, regulate how the brain processes glutamate, an amino acid that helps mediate communication between neurons in the brain.

“There is more and more information pointing to glutamate as having a significant role in antidepressant-treatment outcomes,” said Dr. Gonzalo Laje, one of the study’s authors. “We’re going to hear a lot more about it in upcoming years.”

The researchers looked at more than 700 gene sites, looking for differences between the 6 percent of patients who reported suicidal ideation and the rest of the trial population. Laje said that though this report is being published this month, it must be replicated in order to progressively help those suffering from depression.

Wired also reported the latest genetic tests might mitigate the number of serious health problems and deaths caused by detrimental drug reactions, the article said, citing that those statistics skyrocketed between1998 and 2005. Prescription-related issues during this time period accounted for approximately 468,000 hospitalizations and nearly 90,000 deaths.

Celexa has been prescribed to 8 million people in the United States and 30 million worldwide, according to the drug’s manufacturer, Forest Labs.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Mylan announces new appointments

BY Drew Buono

PITTSBURGH Upon the news of the acquisition involving Merck’s KGaA generic business by Mylan, Mylan released a group of statements regarding new appointments to positions within the company worldwide.

The appointments include: Harry Korman as President, North America; Rajiv Malik as Executive Vice President in charge or Global Technical Operations; Carolyn Myers, Ph.D. President-elect of Dey; Christy Taylor as Chief Operating Officer of Dey; Didier Barret as President of Europe, Middle East, and Africa; Heather Bresch as Chief Operating Officer; and John Montgomery as President, Asia Pacific.

Mylan acquired Merck’s generics for $6.8 billion in cash.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA approves Afluria flu vaccine

BY Drew Buono

AUSTRALIA The Food and Drug Administration has approved CSL’s flu vaccine Afluria, according to The Australian.

The company expects to ship two million doses as part of its first shipment to the U.S. between mid-December and early February. The company expects to increase its export to 20 million doses over the next four years.

“We’ve entered the US market quite late, but over the next few years we hope to increase our export of flu vaccine to the US to 20 million doses,” CSL’s Dr Rachel David said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?